Over the span of a decade, the way Australian medicine addresses iron deficiency in women of reproductive age has been quietly transformed. What was once a rare clinical intervention — intravenous iron infusion — is now received by one in twenty women annually, a seventeen-fold rise that reflects both growing awareness of iron deficiency's debilitating reach and a healthcare system still working to ensure that expanded access translates into equitable, completed care. The surge in treatment, and the $82 million in public spending it now commands, invites a deeper question: whether a medicine's
Iron IV use among Australian women surges 17-fold in a decade
Iron deficiency causes debilitating fatigue, poor concentration, and reduced quality of life in affected women; treatment completion barriers may leave some women undertreated.
Nearly one in four women stop treatment before finishing their prescribed course.
Mark
Why did intravenous iron use jump so dramatically in just one decade? Was there a medical breakthrough?
Mimi
Not really a breakthrough in the drug itself—ferric carboxymaltose has been around. What changed was awareness. Women and doctors became more conscious that iron deficiency was serious and that IV iron could work when pills failed. It became an option people knew to ask for.
Mark
But if it's so effective, why do nearly a quarter of women stop treatment before finishing?
Mimi
That's the puzzle nobody has solved yet. Some women feel better after one or two infusions and think they're done. Others hit a financial wall—hundreds of dollars per infusion adds up fast, even with government support. We don't actually know which reason dominates.
Mark
The geographic variation is striking. Why would treatment rates be three times higher in some regions than others?
Mimi
That's what researchers want to understand. It could be clinical practice differences—some doctors are more comfortable prescribing IV iron. But cost almost certainly plays a role. If you live somewhere with fewer bulk-billing clinics, out-of-pocket expenses become a real barrier.
Mark
Does this mean the increase is actually a good thing, or a sign something's wrong?
Mimi
Both. For women who genuinely need it and can access it, IV iron is transformative. But the variation and the incomplete courses suggest we're not being systematic about it. We're not ensuring equitable access or understanding why women drop out.
Mark
What would equitable access actually look like?
Mimi
Consistent treatment standards across regions, transparent pricing, and follow-up to understand why women stop treatment. Right now we're spending $82 million but not asking hard questions about whether every dollar is reaching women who need it most.
O Pulso
- Iron deficiency — causing crushing fatigue, fractured concentration, and diminished daily life — affects vast numbers of Australian women, yet for years remained undertreated as oral supplements failed or proved intolerable for many.
- Intravenous iron use among women aged 18–44 has exploded seventeen-fold since 2013, with government spending leaping from $1.1 million to $82 million, signalling a fundamental shift in clinical practice driven by both patient demand and growing prescriber awareness.
- Nearly one in four women prescribed the treatment do not complete their full course, raising alarm that financial barriers or premature symptom relief may be leaving a significant portion of patients only partially treated.
- Access is deeply uneven — treatment rates differ by more than threefold across regions, and socioeconomic status, geography, and insurance coverage appear to be shaping who receives adequate care as much as clinical need does.
- Researchers are calling for evidence-based standards and equity-focused policy to ensure the treatment's rapid expansion does not entrench new disparities rather than resolve old ones.
Over the span of a decade, the way Australian medicine addresses iron deficiency in women of reproductive age has been quietly transformed. What was once a rare clinical intervention — intravenous iron infusion — is now received by one in twenty women annually, a seventeen-fold rise that reflects both growing awareness of iron deficiency's debilitating reach and a healthcare system still working to ensure that expanded access translates into equitable, completed care. The surge in treatment, and the $82 million in public spending it now commands, invites a deeper question: whether a medicine's availability is the same as its justice.
In 2024, one in every twenty Australian women of reproductive age received an intravenous iron infusion — a figure that, just a decade earlier, was closer to one in three hundred. The seventeen-fold increase between 2013 and 2024 has fundamentally reshaped how Australian medicine approaches one of the most common deficiencies affecting women, and the financial scale of that shift is equally dramatic: government and patient spending on intravenous iron climbed from $1.1 million to more than $82 million over the same period.
Iron deficiency is common and its consequences are serious. Heavy menstrual bleeding, pregnancy, and breastfeeding steadily deplete the body's reserves, and when deficiency goes untreated, the effects accumulate — fatigue that makes ordinary life feel impossible, concentration that splinters, physical capacity that contracts. For many women, oral iron supplements either fail outright or cause side effects severe enough to prevent consistent use. Intravenous iron bypasses those obstacles, replenishing stores faster and more reliably. Awareness of this option has grown substantially among both patients and clinicians, and general practitioners now write more than 60 percent of prescriptions — a democratisation of access that has helped drive the overall surge.
Yet the expansion conceals troubling fault lines. Treatment rates vary by more than threefold depending on where a woman lives, her income, and who provides her care — raising urgent questions about whether geography and socioeconomic status are quietly determining who receives the most effective treatment. Compounding this, nearly one in four women prescribed the therapy do not complete their full course. Researchers at Flinders University and SAHMRI cannot yet say with certainty why: some women may feel well enough after an initial infusion to stop, while others may face out-of-pocket costs that make continuing impossible. Either way, incomplete treatment risks leaving women partially recovered and still burdened by the deficiency's effects.
Associate Professor Luke Grzeskowiak frames the findings as both a success story and a warning. Intravenous iron is safe and effective, but it is conventionally reserved for cases where oral iron has failed or rapid replenishment is medically necessary — and the seventeen-fold increase suggests use has grown well beyond those boundaries. The researchers' call is clear: access must be equitable, care must remain evidence-based, and the healthcare system must find ways to ensure that women receive not just a prescription, but the full benefit of treatment.
In 2024, one in every twenty Australian women of reproductive age received an intravenous iron infusion. A decade earlier, that figure was closer to one in three hundred. The shift is stark enough to demand explanation—and the numbers behind it are even more striking. Between 2013 and 2024, use of intravenous iron among women aged eighteen to forty-four increased seventeen-fold, a surge that has redrawn the landscape of how Australian medicine treats one of the most common deficiencies affecting women.
The cost has followed the usage upward. Government and patient spending on intravenous iron alone climbed from $1.1 million in 2013 to more than $82 million in 2024. For individual women, the burden can be substantial. Some clinics charge hundreds of dollars per infusion, and those costs fall directly on patients when treatments extend beyond what government schemes cover. Yet despite this investment, nearly one in four women prescribed the treatment do not complete their full course—a gap that researchers at Flinders University, SAHMRI, and collaborating institutions identified as a troubling sign that something in the system is not working as intended.
Iron deficiency itself is unremarkable in its prevalence. Heavy menstrual bleeding, pregnancy, childbirth, and breastfeeding all drain the body's iron reserves. Left untreated, the deficiency becomes debilitating: fatigue that makes ordinary tasks feel impossible, concentration that fragments, physical capacity that shrinks, and a quality of life that narrows. For many women, oral iron supplements—the traditional first line of treatment—either fail to work or trigger side effects severe enough to make compliance impossible. Intravenous iron bypasses these problems. It replenishes stores faster and more reliably, allowing women to feel better sooner. The appeal is obvious, and the research team found that awareness of this option has grown substantially among both patients and clinicians.
The treatment landscape has also shifted in form. Ferric carboxymaltose, a newer formulation of intravenous iron, now accounts for nearly 94 percent of all prescriptions. General practitioners, not specialists, write more than 60 percent of these prescriptions—a democratization of access that has helped drive the overall increase. The Pharmaceutical Benefits Scheme data that researchers analyzed from 2013 to 2024 shows the climb with precision: from 0.3 women per 100 in 2013 to 5.0 women per 100 in 2024.
But the surge masks profound inequities. Treatment rates vary dramatically depending on where a woman lives, her age, whether she holds a concession card, and who prescribes her care. In some parts of Australia, rates of intravenous iron use are more than three times higher than in others. These differences raise urgent questions about whether all women are receiving equitable access to the most appropriate treatment, or whether geography, income, and insurance status are determining who gets better care.
The incomplete treatment courses compound the concern. Researchers do not yet know why nearly a quarter of women stop treatment before finishing their prescribed regimen. Some may feel better after an initial dose and decide further infusions are unnecessary. Others may face financial barriers that make completing the course impossible. The distinction matters: women who do not complete treatment may not receive the full benefit, leaving them partially treated and potentially still struggling with the fatigue and reduced capacity that iron deficiency causes.
Associate Professor Luke Grzeskowiak, a clinical pharmacist at Flinders University, frames the findings as a call for precision and equity. Intravenous iron is generally safe and effective, he notes, but it is typically reserved for cases where oral iron has failed, cannot be tolerated, or when rapid iron replacement is medically necessary. The seventeen-fold increase suggests the treatment is becoming more common than those guidelines alone would predict. The researchers emphasize that the use must remain evidence-based, that access must be equitable, and that the system must ensure women receive the right care at the right time. The question now is whether Australia's healthcare system can deliver on that promise.
Citações Notáveis
For women struggling with iron deficiency, particularly when oral iron tablets are ineffective or cause troublesome side effects, intravenous iron can be an important treatment option. It can replenish iron stores more quickly and help women feel better sooner.— Associate Professor Luke Grzeskowiak, Flinders University
We need to better understand what is driving these differences and whether all women are receiving equitable access to the most appropriate treatment. Cost could also be playing a role.— Dr Gizat Kassie, SAHMRI
Quer a matéria completa?
Leia o original em EurekAlert! ↗
Health & Medicine